IL2 and neoplasm: As proof of principle, we first validated the contribution of the Neoscreen approach by interrogating TILs from two tumor specimens (patients 6 and 7; Supplementary Tables 1 and 4) where we could readily identify four neoepitope reactivities among (conventional) TILs expanded with IL-2.